Placebo News and Research

RSS

SANA releases new video on Benefits of Soyfoods for Active Adults

The Soyfoods Association of North America today announced that it has released a video on the Benefits of Soyfoods for Active Adults demonstrating how soyfoods can help you stay fit and healthy. Americans who are trying to lead healthier lives will find that soyfoods boost their energy, improve heart health, and provide antioxidants.

15 Feb 2013

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today the U.S. commercial launch of UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

14 Feb 2013

Rivaroxaban ruled out for extended thromboprophylaxis

The benefits of extended prophylactic anticoagulation with rivaroxaban in acutely ill hospital patients are outweighed by an increased bleeding risk, shows a study in The New England Journal of Medicine.

14 Feb 2013

Probiotics shows promise in reducing both incidence and severity of necrotizing enterocolitis

"Good" bacteria that live in our intestines have been linked with a variety of health benefits, from fighting disease to preventing obesity. In a new study, Kriston Ganguli of Massachusetts General Hospital for Children and Harvard Medical School and her colleagues have discovered another advantage to these friendly microscopic tenants: Chemicals secreted by good bacteria that typically live in the intestines of babies could reduce the frequency and severity of a common and often-lethal disease of premature infants.

14 Feb 2013

Blood’s tendency to clot may contribute to white matter hyperintensities in post-menopausal women

New Mayo Clinic research suggests that blood may hold clues to whether post-menopausal women may be at an increased risk for areas of brain damage that can lead to memory problems and possibly increased risk of stroke. The study shows that blood's tendency to clot may contribute to areas of brain damage called white matter hyperintensities.

14 Feb 2013

New drug delivery system can reduce size of ovarian tumors by as much as 83%

By loading fragile RNA into silicon nanoparticles, researchers from The Methodist Hospital and two other institutions found a new drug delivery system can reduce the size of ovarian tumors by as much as 83 percent -- and stop tumor growth in chemotherapy-resistant ovarian cancer tissue.

13 Feb 2013

Risk of preterm birth associated with intra-amniotic debris and shortened cervix

In a study to be presented on February 14 between 8 a.m. and 10 a.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting -, in San Francisco, California, researchers will report findings suggesting an increased risk of early (less than 35 weeks) preterm birth when intra-amniotic debris is present in nulliparous women with a short cervix.

13 Feb 2013

LASAG trial for severe influenza initiated

...

12 Feb 2013

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma is a devastating disease. There are roughly 20-25,000 new cases per year in the United States and it is increasing for some reason.

12 Feb 2013

Arrhythmia may confound heart failure treatment

Meta-analysis findings question whether beta-blocker treatment remains effective in patients who have heart failure with reduced left ventricular ejection fraction if they also have atrial fibrillation.

11 Feb 2013

New insights on role of placebo in depression

A randomized controlled trial published in one of the last issue of Psychotherapy and Psychosomatics unravels new insights on the role of placebo in depression.

10 Feb 2013

Neurocrine Biosciences fourth quarter net income increases to $9.5 million

Neurocrine Biosciences, Inc. today announced its financial results for the quarter and year ended December 31, 2012.

9 Feb 2013

Omega-3 fatty acids can prevent sudden cardiac death in dialysis patients

Medical literature long has touted the benefits of omega-3 fatty acids for the heart. But until now, researchers have not studied the potential benefit for people on hemodialysis, who are among the highest-risk patients for sudden cardiac death.

9 Feb 2013

Antibiotics help severely malnourished children recover

Giving severely malnourished children antibiotics in addition to nutritional therapy significantly improves their chances of making a full recovery compared with nutritional therapy alone, say researchers.

7 Feb 2013

First new TB vaccine in century fails initial testing

The first of a series of new vaccines that have been developed to combat tuberculosis failed to show efficacy compared with placebo in South African infants, show results from a phase II trial.

7 Feb 2013

Steroid injections not advisable for tennis elbow

Results from a placebo-controlled trial show that patients given corticosteroid injections for treatment of unilateral lateral epicondylalgia, or tennis elbow, have a worse outcome after 1 year than those treated with placebo.

6 Feb 2013

Ramipril puts spring in step of patients with intermittent claudication

Six months of treatment with the angiotensin-converting enzyme inhibitor ramipril produces notable improvements in the walking ability of patients with peripheral artery disease and intermittent claudication, shows a large randomized trial.

6 Feb 2013

Elan agrees to restructure Tysabri collaboration with Biogen Idec

Elan Corporation, plc today announced that it has agreed to restructure the Tysabri® collaboration with Biogen Idec.

6 Feb 2013

Ramipril may improve pain-free walking among patients with PAD and intermittent claudication

Among patients with peripheral artery disease and intermittent claudication (pain in the calf that comes and goes, typically felt while walking), 24 weeks of treatment with the angiotensin-converting enzyme (ACE) inhibitor ramipril was associated with improvement in pain-free and maximum walking times and the physical health aspect of quality of life, according to a study appearing in the February 6 issue of JAMA.

6 Feb 2013

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Teva Pharmaceutical Industries Ltd. announced today enrollment of the first patient in the MODERATO study - a Phase IV clinical study designed to evaluate the effect of AZILECT (rasagiline tablets) on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).

6 Feb 2013